Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

References

• ReudelhuberTLRamlaDChiuLProteolytic processing of human prorenin in renal and non-renal tissuesKidney Int199446152215247699995
   PubMed Web of Science ®Google Scholar
• DanserAHDerkxFHSchalekampMADeterminants of inter-individual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humansJ Hypertens1998168538629663926
   PubMed Web of Science ®Google Scholar
• GaddamKKOparilSRenin inhibition: should it supplant ACE inhibitors and ARBS in high risk patientsCurr Opin Nephrol Hypertens20081748449018695389
   PubMed Web of Science ®Google Scholar
• NguyenGDelarueFBurckleCPivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to reninJ Clin Invest20021091417142712045255
   PubMed Web of Science ®Google Scholar
• NguyenGRenin/prorenin receptorsKidney Int20066915030616672920
   PubMed Web of Science ®Google Scholar
• CampbellDJCritical review of prorenin and (Pro)renin receptor researchHypertension2008511259126418347225
   PubMed Web of Science ®Google Scholar
• DanserAHDeinumJRenin, prorenin and the putative (pro)renin receptorHypertension2005461069107616186442
   PubMed Web of Science ®Google Scholar
• IchiharaAKaneshiroYTakemitsuTNonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertensionHypertension2006a4789490016585419
   PubMed Web of Science ®Google Scholar
• IchiharaAKaneshiroYTakemitsuTContribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damageJ Am Soc Nephrol2006b172495250316885412
   PubMed Web of Science ®Google Scholar
• SarisJJ‘t HoenPAGarreldsIMProrenin induces intracellular signaling in cardiomyocytes independently of angiotensin IIHypertension20064856457116940215
   PubMed Web of Science ®Google Scholar
• BurckléCAJan DanserAHMüllerDNElevated blood pressure and heart rate in human renin receptor transgenic ratsHypertension20064755255616401765
   PubMed Web of Science ®Google Scholar
• HuangYWongamorhthamSKastingJRenin increases messangial cell transforming growth factor-b1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanismsKidney Int20066910511316374430
   PubMed Web of Science ®Google Scholar
• OliverJAReceptor-mediated actions of renin and proreninKidney Int200669131516374416
   PubMed Web of Science ®Google Scholar
• DanserAHVan Den DorpelMADeinumJRenin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathyJ Clin Endocrinol Metab1989681601672642484
   PubMed Web of Science ®Google Scholar
• WilsonDMLuetscherJAPlasma prorenin activity and complications in children with insulin-dependent diabetes mellitusN Engl J Med1990323110111062215578
   PubMed Web of Science ®Google Scholar
• DeinumJRonnBMathiesenEIncrease in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitusDiabetologia1999421006101010491762
   PubMed Web of Science ®Google Scholar
• IchiharaASuzukiFNakagawaTProrenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor deficient miceJ Am Soc Nephrol2006c719501961
   Google Scholar
• RosendorffCThe renin-angiotensin system and vascular hypertrophyJ Am Coll Cardiol1996288038128837552
   PubMed Web of Science ®Google Scholar
• DzauVTissue angiotensin and pathobiology of vascular disease: a unifying hypothesisHypertension2001371047105211304501
   PubMed Web of Science ®Google Scholar
• GradmanAHKadRRenin inhibition in hypertensionJ Am Coll Cardiol20085151952818237679
   PubMed Web of Science ®Google Scholar
• NussbergerJRenin inhibitorsOparilSWeberMAHypertension, A Companion to Brenner and and Rector’s The kidney2nd edPhiladelphiaElsevier2005754764
   Google Scholar
• NussbergerJWuerznerJJensenCAngiotensin II supression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalaprilHypertension200239e1e811799102
   PubMed Web of Science ®Google Scholar
• DieterleWCorynenSVaidyanathanSEffect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjectsBr J Clin Pharmacol20045843343615373937
   PubMed Web of Science ®Google Scholar
• DieterleWCorynenSVaidyanathanSPharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidineInt J Clin Pharmacol Ther20054352753516300168
   PubMed Web of Science ®Google Scholar
• DieterichHKempCVaidyanathanSPharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteersClin Pharmacol Therap2006a79P12(abstract).
   Web of Science ®Google Scholar
• DieterichHKempCVaidyanathanSAliskiren, the first in a new class or orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteersClin Pharmacol Therap2006b79P64(abstract).
   Web of Science ®Google Scholar
• FisherNDDanserJNussbergerJRenal and hormonal responses to direct renin inhibition with aliskiren in healthy humansCirculation20081173199320518559696
   PubMed Web of Science ®Google Scholar
• AziziMMénardJBisseryAPharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruptionJ Am Soc Nephrol2004153126313315579516
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSAPatelSEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trialLancet200737022122917658393
   PubMed Web of Science ®Google Scholar
• SealeyJELaraghJHAliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectivenessAm J Hypertens20072058759717485026
   PubMed Web of Science ®Google Scholar
• SealeyJELaraghJHAliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively risesAm J Hypertens20092211212118802434
   PubMed Web of Science ®Google Scholar
• MénardJAziziMThe difficult conception, birth and delivery of a renin inhibitor: controversies around aliskirenJ Hypertens2007251775178217762637
   PubMed Web of Science ®Google Scholar
• FeldmanDLJinLXuanHEffects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen)27 ratsHypertension20085213013618490518
   PubMed Web of Science ®Google Scholar
• VillamilAChysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens20072521722617143194
   PubMed Web of Science ®Google Scholar
• AndersenKWeinbergerMHEganBComparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trialJ Hypertens20082658959918300872
   PubMed Web of Science ®Google Scholar
• BrownMJAliskirenCirculation200811877378418695203
   PubMed Web of Science ®Google Scholar
• DietzRDechendRYuCMEffects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1J Renin Angiotensin Aldosterone Syst2008916317518957387
   PubMed Web of Science ®Google Scholar
• NickenigGSimanenkovVLemboGEfficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-respondersBlood Press Suppl20082314019203020
   PubMedGoogle Scholar
• SchmiederREPhilippTGuerediagaJLong-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazideCirculation200911941742519139391
   PubMed Web of Science ®Google Scholar
• MikhailNGolubMSTuckMLObesity and hypertensionProg Cardiovasc Dis199942395810505492
   PubMed Web of Science ®Google Scholar
• BrownCDHigginsMDonatoKABody mass index and the prevalence of hypertension and dyslipidemiaObes Res2000860561911225709
   PubMedGoogle Scholar
• GarrisonRJKannelWBStokesJ3rdCastelliWPIncidence and precursors of hypertension in young adults: the Framingham Offspring StudyPrev Med1987162352513588564
   PubMed Web of Science ®Google Scholar
• BramlagePPittrowDWittchenHUHypertension in overweight and obese primary care patients is highly prevalent and poorly controlledAm J Hypertens20041790491015485752
   PubMed Web of Science ®Google Scholar
• RahmouniKCorreiaMLHaynesWGObesity-associated hypertension: new insights into mechanismsHypertension20054591415583075
   PubMed Web of Science ®Google Scholar
• JordanJEngeliSBoyeSWDirect renin inhibition with aliskiren in obese patients with arterial hypertensionHypertension2007491047105517353513
   PubMed Web of Science ®Google Scholar
• HabibiJWhaley-ConnelAHaydenMRRenin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 ratEndocrinology20081495643565318653711
   PubMed Web of Science ®Google Scholar
• UresinYTaylorAAKiloCEfficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJ Renin-Angiotensin-Aldosterone System2007819020018205098
   PubMed Web of Science ®Google Scholar
• PilzBShagdarsurenEWellnerMAliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic ratsHypertension20054656957616103264
   PubMed Web of Science ®Google Scholar
• ShagdarsurenEWellnerMBraesenJHComplement activation in angiotensin II-induced organ damageCirc Res20059771672416109917
   PubMed Web of Science ®Google Scholar
• KellyDJZhangYMoeGAliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropaty in ratsDiabetologia2007502398240417828524
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPSchjoedtKJTime course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetesKidney Int2008731419142518337712
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBAliskiren combined with losartan in type 2 diabetes and nephropatyN Engl J Med20083582433244618525041
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med200034214515310639539
   PubMed Web of Science ®Google Scholar
• StrawnWBChappellMCDeanRHInhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemiaCirculation20001011586159310747353
   PubMed Web of Science ®Google Scholar
• NussbergerJAubertJFBouzoureneKRenin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipineHypertension2008511306131118391092
   PubMed Web of Science ®Google Scholar
• ImanishiTTsujiokaHIkejimaHRenin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changesHypertension20085256357218645051
   PubMed Web of Science ®Google Scholar
• LuHRateriDLFeldmanDLRenin inhibition reduces hypercholesterolemia-induced atherosclerosis in miceJ Clin Invest200811898499318274671
   PubMed Web of Science ®Google Scholar
• WestermannDRiadALettauORenin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressureHypertension2008521068107518955663
   PubMed Web of Science ®Google Scholar
• SolomonSAppelbaumEManningWJEffect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both, on left ventricular mass in patients with hypertension and left ventricular hypertrophyCirculation200911953053719153265
   PubMed Web of Science ®Google Scholar
• McMurrayJJPittBLatiniREffects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failureCirc Heart Fail20081124
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy of Aliskiren in PostMyocardial Infarction Patients (ASPIRE)Accessed 16 February 2009. URL: http://clinicaltrials.gov/ct2/show/NCT00414609?term=aliskiren+and+heart+failure&rank=2
   Google Scholar
• ParvingHHBrennerBMMcMurrayJJAliskiren trial in type 2 diabetes using cardiorenal endpoints (ALTITUDE): rationale and study designNephrol Dial Transplant2009doi:10.1093/ndt/gfn721.
   Google Scholar
• ReudelhuberTLReninOparilSWeberMAHypertension, 2nd ed. A Companion to Brenner and Rector’s The kidneyPhiladelphiaElsevier20058994
   Google Scholar